AstraZeneca PLC Form 6-K Filing Summary

This filing details the US FDA approval of AstraZeneca's Baxfendy (baxdrostat) as a first-in-class aldosterone synthase inhibitor for treating hypertension in adults. Hypertension affects 1.4 billion people globally, with about 50% of US patients on multiple medications still struggling with elevated blood pressure. Baxfendy works by inhibiting aldosterone synthase, a novel approach to lowering blood pressure and reducing cardiovascular and kidney risks. The approval is based on positive results from the BaxHTN Phase III trial, which showed statistically significant reductions in systolic blood pressure with Baxfendy. The drug was generally well-tolerated. The filing also provides background on hypertension, the mechanism of action of Baxfendy, details of the BaxHTN trial, and AstraZeneca's broader CVRM strategy.